April 16th 2024
Serial testing of ctDNA could improve risk stratification for determining adjuvant treatment in patients with high-risk muscle-invasive bladder cancer.
Adjuvant nivolumab extended DFS, NUTRFS, and DMFS vs placebo and showed for the first time an improvement in OS in patients with high-risk muscle-invasive urothelial cancer.
April 12th 2024
The intravesical gene therapy elicited durable remissions in a high percentage of patients with high-risk, BCG-unresponsive non–muscle invasive bladder cancer.
July 12th 2021
Vinayak G. Wagaskar, MBBS, discusses potential explanations for a paradoxical relationship between obesity and outcomes observed in prostate cancer.
Evangelia Sereti, MSc, PhD, discusses the next steps with the combination of NOV202 and olaparib in BRCA1/2-mutated prostate cancer.
Treatment with darolutamide induced a low cumulative incidence of hormone treatment–related adverse effects that was comparable to treatment with placebo in patients with nonmetastatic castration-resistant prostate cancer, according to findings from a safety analysis of the phase 3 ARAMIS trial.
Abiraterone acetate plus prednisone should be considered as the first treatment choice for patients with newly diagnosed metastatic castration-resistant prostate cancer if fatigue is a concern.
Eighty-five percent of patients with nonmetastatic castration-resistant prostate cancer who crossed over from placebo to darolutamide in the phase 3 ARAMIS trial experienced a maximum prostate-specific antigen decline of at least 50% at any time of crossover.
Investigators demonstrated that the benefit of androgen deprivation therapy was extended with the addition of apalutamide for patients with metastatic castration-sensitive prostate cancer regardless of disease volume.
Intense androgen receptor inhibition with neoadjuvant apalutamide did not complicate robotic prostatectomy surgical outcomes.
July 10th 2021
Patients with a urological cancer who were also infected with COVID-19 and undergoing elective surgery for their disease, were found to have a significantly higher likelihood of experiencing respiratory complications and mortality than those without the virus.
Sequential combination treatment with mytomicin chemotherapy and Bacillus Calmette-Guérin (BCG) showed comparable safety compared with BCG alone in patients with high-risk non-muscle–invasive bladder cancer.
Evangelia Sereti, MSc, PhD, discusses the preclinical efficacy of NOV202 plus olaparib in BRCA1/2-mutated prostate cancer cells.
Vinayak G. Wagaskar, MBBS, discusses the rationale to evaluate the relationship between obesity paradigm and outcomes in prostate cancer.
July 9th 2021
The provision of urologic care underwent a significant decline during the height of the COVID-19 pandemic across all demographic groups and practice settings in the United States, regardless of the timing of stay-at-home order mandates.